The board of directors of the Yestar International Holdings Company Limited announced that based on a preliminary review and assessment of the unaudited consolidated management accounts of the Group for the six months ended 30 June 2016, the group is expected to record an increase of not less than 80% and 55% in its consolidated net profit of the group and consolidated net profit attributable to the owners of the parent, respectively, for the six months ended 30 June 2016 as compared with that of the six months ended 30 June 2015 (unaudited consolidated net profit of the Group and unaudited consolidated net profit attributable to the owners of the parent for the six months ended 30 June 2015 amounted to approximately RMB 67,519,000 and RMB 55,758,000, respectively). The substantial increase is mainly attributable to the outstanding performance of In Vitro Diagnostic business with high profit margin; and the consolidation of financial information of Shanghai Anbaida group companies to the Group upon completion of such acquisition.